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Despite recent advances in diagnosis and therapy, pros-
tate cancer remains the most frequently diagnosed non-
skin cancer in the United States and the third leading
cause of cancer deaths. Failure of chemotherapies and
hormone-deprivation therapies is the major cause of
death in patients with castration-resistant prostate can-
cer (CRPC). Currently, the androgen inhibitors Enzalu-
tamide and Abiraterone are approved for treatment of
metastatic CRPC. Enzalutamide is a second-generation
androgen antagonist with no agonist activity. Abirater-
one is a cytochrome P450 inhibitor that blocks adrenal
and intratumoral androgen production. Here we show
for the first time that both Enzalutamide and Abirater-
one induce immunogenic modulation in human prostate
tumor cells, rendering them more sensitive to T cell-
mediated lysis, and that these immunomodulatory activ-
ities are androgen receptor (AR)-dependent. In studies
reported here, exposure in vitro and in vivo of human
prostate carcinoma cells to Enzalutamide significantly
down-regulated the anti-apoptotic NAIP gene. Func-
tional analysis revealed that NAIP played a critical role
in inducing CTL sensitivity. Amplification of AR is a
major mechanism of resistance to androgen-deprivation
therapy (ADT). Here, we show that Enzalutamide
enhances sensitivity to immune-mediated killing of pros-
tate tumor cells that overexpress AR. The immunomo-
dulatory properties of Enzalutamide and Abiraterone
provide a rationale for their use in combination with
immunotherapeutic agents in CRPC, particularly for
patients with minimal response to Enzalutamide or
Abiraterone alone, or for patients who have developed
resistance to ADT.
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